AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Clene to submit ALS NDA in Q1 2026, phase 3 trial to start H1 2026.
ByAinvest
Thursday, Nov 13, 2025 8:19 am ET1min read
Clene Inc. is concluding ALS biomarker data analyses and expects to submit a New Drug Application in Q1 2026 under an accelerated approval pathway. The FDA advised Clene to request a Type C meeting to review further analyses. The Company plans to dose the first patient in the Phase 3 RESTORE-ALS trial in H1 2026. Clene's cash and cash equivalents stood at $7.9 million as of September 30, 2025, with a cash runway extended into Q2 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet